Information for Providers on Antidepressants During Pregnancy & Breast Feeding - September 2011

This chart is produced by the University of Illinois at Chicago (UIC) Perinatal Mental Health Project as a summary of research on antidepressants in human pregnancy and breastfeeding.

Sources of data:
- **Pregnancy data:** Data summarized here are from controlled studies in human pregnancy. The Food and Drug Administration (FDA) Pregnancy Risk Categories, as found in the Physicians' Desk Reference¹, are based on both animal and human studies. No antidepressants are yet specifically FDA-approved for use during pregnancy. All antidepressants cross the placenta, so there are none that are ‘Category A’ ("no risk"). Medications that are non-teratogenic in animal studies but have never been studied in humans are classified as ‘Category B’. Since teratogenicity does not generalize across species, a ‘Category B’ classification does not imply greater safety in human pregnancy than a ‘Category C’ or ‘Category D’ classification. Several medications have been shifted from ‘Category B’ to ‘Category C’ or ‘Category D’ as their risks became better known.
- **Breastfeeding data:** Data about antidepressant effects on breastfeeding babies are predominantly from case reports and case series. For medications with no reported side effects, that does not necessarily mean the medication is “safe”; often it means there are few case reports available. Reported percents of maternal dose to breastfeeding babies are weight-adjusted estimates that include the agent and its active metabolite(s).

*Specific references are available on request.

General guideline:
- Optimal treatment is based on individual patient characteristics and clinical judgment, especially weighing medication risks against risks of untreated illness. Risks of untreated perinatal depression may include preterm birth and other obstetric complications, increased risk of infection and difficult temperament in the infant, impaired parenting, and psychological effects such as impaired cognitive development, emotional and behavioral problems and increased reactivity to stress in children.

Antidepressants as a group may be associated with following risks:
- Increased risk of preterm birth and lower gestational age at birth, but without adverse effects on birth weight or Apgar scores
- Increased risk of miscarriage, but rates within norms of the general population.

SSRI antidepressants as a group (citalopram, escitalopram, fluoxetine, paroxetine, sertraline) may be associated with the following risks:
- Neonatal side effects, including respiratory distress, excessive crying, changes in sleep and behavioral state, difficulty sleeping, increased or decreased muscle tone, hyperreflexia, seizures, and/or cardiac arrhythmias.
- Most studies have found no increased risk of gestational hypertension. One retrospective study² found a possible increased risk of gestational hypertension.
- Possible increased risk of persistent pulmonary hypertension in the newborn with exposure later in pregnancy.
- Most studies have found no increased risk of birth defects. One retrospective study² found a possible increased risk of anencephaly, craniosynostosis, and omphalocele; another³ found an increased risk of anomalies in general, although absolute risks were small.
- Delay in lactation, however the delay was only for 14 hours on average.
- Kaiser Study showed 2-fold increased risk for Autism spectrum disorder with use of SSRI within one year of delivery and 3-fold increased risk with SSRI use in first trimester.

For questions, references, or permission to reprint, call the UIC Perinatal Mental Health Project at 1-800-573-6121

© 2011 The Board of Trustees of the University of Illinois, UIC Perinatal Mental Health Project. All rights reserved.
### Information for Providers on Antidepressants During Pregnancy & Breast Feeding - September 2011

<table>
<thead>
<tr>
<th>Antidepressant</th>
<th>Advantages During Pregnancy</th>
<th>Teratogenicity</th>
<th>Other Disadvantages During Pregnancy</th>
<th>Estimated % of Maternal Dose to Breastfeeding Baby</th>
<th>Reported Side Effects to Breastfeeding Babies</th>
</tr>
</thead>
</table>
| Bupropion      | • Fewer sexual side effects  | Morphologic - limited evidence of cardiac malformations; increased risk for pulmonary hypertension **Behavioral** - limited evidence of increased risk of ADHD | • Limited data available  
• Lowers seizure threshold  
• Can cause insomnia  
• May increase risk of miscarriage | 2.0% | Seizures |
|                | • Less risk of weight gain  |               |                                      |                                                 |                                             |
|                | • Helps with smoking cessation |               |                                      |                                                 |                                             |
| Citalopram     | • Few interactions with other medications | Morphologic - risk of neural tube defect **Behavioral** - none found | • Limited data available | 0.7% - 9.0% | Uneasy sleep, drowsiness, irritability, weight loss |
| Desipramine    | • More studies in human pregnancy, including neurodevelopmental follow-up | Morphologic - none found  
**Behavioral** - none found | • Maternal side effects additive to pregnancy effects (sedation, constipation, tachycardia)  
• Orthostatic hypotension, risking decreased placental perfusion  
• Fetal and neonatal side effects: tachycardia, urinary retention | 1.0% | Agitation of newborn, potential triggering of seizure activity if there is a history of seizures |
| Duloxetine     | • Also treats diabetic peripheral neuropathic pain | Morphologic - unknown  
**Behavioral** - unknown | • No systematic studies in human pregnancy | 0.1% | Unknown |
| Escitalopram   | • Few interactions with other medications | Morphologic - unknown  
**Behavioral** - unknown | • No systematic studies in human pregnancy | 3.9% - 7.9% | Enterocolitis |
| Fluoxetine     | • More studies in human pregnancy, including meta-analysis and neurodevelopmental follow-up | Morphologic - increased risk of cardiovascular malformations*  
**Behavioral** - none found | • More reports of neonatal side effects than most other antidepressants | 1.2% - 12.0% | Excessive crying, irritability, vomiting, watery stools, difficulty sleeping, tremor, somnolence, hypotonia, decreased weight gain, hyperglycemia |
| Mirtazapine    | • Fewer sexual side effects  | Morphologic - none found  
**Behavioral** - unknown | • Limited data available  
• Can cause excessive weight gain  
• Tends to be sedating  
• May increase risk of preterm birth | 0.6% - 2.8% | None |
|                | • Helps restore appetite in women who are not gaining weight  
• Less likely to exacerbate nausea and vomiting |               |                                      |                                                 |                                             |
| Nortriptyline  | • More studies in human pregnancy, including neurodevelopmental follow-up | Morphologic - none found  
**Behavioral** - none found | • Maternal side effects additive to pregnancy effects (sedation, constipation, tachycardia)  
• Orthostatic hypotension, risking decreased placental perfusion  
• Fetal and neonatal side effects: tachycardia, urinary retention | 1.3% | None |

*Increased risk of cardiovascular malformations compared to untreated control subjects.*
<table>
<thead>
<tr>
<th>Antidepressant</th>
<th>Advantages During Pregnancy</th>
<th>Teratogenicity</th>
<th>Other Disadvantages During Pregnancy</th>
<th>Estimated % of Maternal Dose to Breastfeeding Baby</th>
<th>Reported Side Effects to Breastfeeding Babies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paroxetine</td>
<td>Minimal association with cardiovascular malformations but may be optimal for some individual parents</td>
<td>Morphologic - possible increased risk of cardiovascular malformations Behavioral - unknown</td>
<td>More reports of neonatal side effects than most other antidepressants ACOG recommends fetal echo for all exposed fetuses</td>
<td>0.1% - 4.3%</td>
<td>Intability, sleepiness, constipation, SADH</td>
</tr>
<tr>
<td>Sertraline</td>
<td>Relatively well-studied in human pregnancy Fewer reports of neonatal side effects than other antidepressants</td>
<td>Morphologic - unlikely increased risk of omphalocele and septal defects Behavioral - none found</td>
<td>Minimal association with omphalocele and septal defects</td>
<td>0.4% - 2.3%</td>
<td>Drug of choice by OBs &amp; Pediatricians</td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>None specific, but may be optimal for some individual patients</td>
<td>Morphologic - none found Behavioral - unknown</td>
<td>Limited data available</td>
<td>5.2% - 7.6%</td>
<td>Decreased weight gain</td>
</tr>
<tr>
<td>Desvenlafaxine</td>
<td>None specific, but may be optimal for some individual patients</td>
<td>Morphologic - unknown Behavioral - unknown</td>
<td>No systematic studies in human pregnancy</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

* Findings from one study at variance with other data, perhaps due to methodological flaws

For questions, call the UIC Perinatal Mental Health Project at 1-800-573-6121